Last reviewed · How we verify
Bryophyllum
At a glance
| Generic name | Bryophyllum |
|---|---|
| Also known as | dried leave press juice, provided by Weleda AG, Arlesheim, Switzerland |
| Sponsor | University of Zurich |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bryophyllum Pinnatum Tea as a Novel Treatment for Recurrent Kidney Stone Formers (EARLY_PHASE1)
- Assessing the Therapeutic Potential of a Traditional Botanical Remedy for Menstrual Pain: Insights From a Prospective Observational Analysis (PHASE4)
- Perceived Changes in Anxiety Symptom Burden During Treatment With Bryophyllum Pinnatum and Tolerability (PHASE4)
- Bryophyllum Pinnatum Treatment of Anxiety Related to Signs of Preterm Birth (PHASE2)
- Effectiveness of Bryophyllum in Nocturia-Therapy (NA)
- The Impact of Bryophyllum on Preterm Delivery (PHASE4)
- Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder (PHASE2, PHASE3)
- Bryophyllum Versus Placebo for Overactive Bladder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bryophyllum CI brief — competitive landscape report
- Bryophyllum updates RSS · CI watch RSS
- University of Zurich portfolio CI